Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Patients:
- People diagnosed with high-risk acute myeloid leukaemia (AML) that is newly diagnosed
- People with AML that has not responded to initial treatment
- People with AML that has come back after previous treatment
- People who are functioning reasonably well in daily life, as measured by a standard health scoring system (a score of 70 or above on the Karnofsky or Lansky scale — confirm with trial site what this means for your situation)
- People who have given written agreement to take part in the trial
Donors (a family member providing cells):
- A family member who is a "half-match" (haploidentical) donor
- A donor who meets standard medical criteria for donating cells through a collection process called apheresis
- A donor who has given written agreement to take part
Who may not be able to join:
Patients:
- People who have an infection that is not currently under control
- People with serious liver problems, based on specific blood test results being five times or more above the normal range for their age
- People who test positive for HIV
Donors:
- People who are pregnant
- People who test positive for HIV, hepatitis B, or hepatitis C
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Olga Aleinikova, MD, Prof, Belarussian Research Center for Pediatric Oncology, Hematology and Immunology
Phone: +375296341853
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective Response Rate (ORR) (PR+ MLFS+CRi +CR); Leukemia-free survival (LFS); Overall survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.